Key points are not available for this paper at this time.
Stapokibart (CM310) is a humanized IL-4Rα monoclonal antibody currently undergoing phase 3 trials for type 2 inflammatory diseases. In contrast to dupilumab, which bound exclusively to human IL-4Rα, stapokibart demonstrated cross-species reactivity to IL-4Rα from human, cynomolgus monkey, and rat. Stapokibart exhibited comparable blocking activity to dupilumab. Epitope mapping revealed that stapokibart bound to distinct sites on IL-4Rα compared to dupilumab.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wei Liu
Yan Zhao
Yanyun He
iScience
Peking University
Peking University People's Hospital
Bioscience (China)
Building similarity graph...
Analyzing shared references across papers
Loading...
Liu et al. (Tue,) studied this question.
www.synapsesocial.com/papers/68e5c751b6db64358755daf4 — DOI: https://doi.org/10.1016/j.isci.2024.110721
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: